Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis

• Main Authors: Michael J. Cork (Author), Diamant Thaçi (Author), Lawrence F. Eichenfield (Author), Peter D. Arkwright (Author), Zhen Chen (Author), Ryan B. Thomas (Author), Matthew P. Kosloski (Author), Ariane Dubost-Brama (Author), Randy Prescilla (Author), Ashish Bansal (Author), Noah A. Levit (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background For children aged 6-11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to info...